Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib PK in hepatic impairment
NCT05828277Phase 1Withdrawn
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of repotrectinib in solid tumor (3 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Area under the plasma concentration-time curve and Maximum Observed Plasma Concentration. Planned start Jul 2022; status: withdrawn.
02
Drugs
repotrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05828277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828277.